Guggenheim downgrades Merus stock to Neutral following Genmab acquisition
NegativeFinancial Markets

Guggenheim has downgraded Merus stock to Neutral after Genmab's recent acquisition, signaling potential concerns about Merus's future performance. This decision reflects the market's cautious stance on how the acquisition might impact Merus, which could affect investor confidence and stock valuation. Understanding these shifts is crucial for stakeholders as they navigate the evolving landscape of biotech investments.
— Curated by the World Pulse Now AI Editorial System